Please reload

Recent Posts

Boustead Securities Client ADOMANI First to IPO on NASDAQ Under the Jobs Act Regulation A+. Shares Up 92%.

June 19, 2017

1/1
Please reload

Featured Posts

Boustead Client PetCure Oncology Reaches Milestone, Treating 3,000th Pet With Advanced Radiation Therapy

October 1, 2019

 

Boustead Securities and FlashFunders client PetCure Oncology, LLC, a company providing veterinary cancer treatment utilizing noninvasive stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT), treated its 3,000th pet with advanced radiation therapy this week, reaching a historic milestone in the fast-growing field of veterinary radiation oncology.​

 

The treatment was delivered to an 11-year-old boxer named Roman. Roman’s dedicated pet mom, Jacqueline Toth, is also a cancer survivor. When she was diagnosed with cancer five years ago, her loyal dog was there to help her through it.

 

“I knew I had to live for Roman,” recalled Toth. “He’s my child and all I have. Really, Roman saved my life. I love him!”

 

When Roman was diagnosed with a brain tumor, Toth put her life on hold to seek out treatment from PetCure Oncology at Arizona Veterinary Oncology in Phoenix. She closed her business for the week and traveled nearly 400 miles from Las Cruces, New Mexico, so that Roman could receive stereotactic radiation (SRS/SRT) from veterinary radiation oncologist Dr. Eric Boshoven and his team.

 

Roman [pictured] became the 3,000th pet treated by PetCure Oncology,

receiving advanced radiation therapy for his brain tumor.

   

“Pets with cancer are now receiving the same advanced quality of care as their human companions,” said Dr. Neal Mauldin, chief medical officer of PetCure Oncology. “The pets we have treated and the data we have collected indicate that modern radiation therapy can lead to better outcomes than ever before. For many pets with cancer, this means living longer with an improved quality of life.”

 

Dr. Mauldin, a triple-board certified veterinary specialist in radiation oncology, medical oncology and internal medicine, leads PetCure’s team of seven board-certified veterinary radiation oncologists – the largest and most experienced in the country. All 3,000 of the pets they have treated with radiation therapy have been treated within clinical protocols established by PetCure Oncology in an effort to ensure optimal outcomes with a priority on pet safety and quality.

 

While advanced radiation therapy, or stereotactic radiation (SRS/SRT), is still relatively new in veterinary medicine, the 3,000 pets treated on-protocol by PetCure Oncology represent an unprecedented source of data for clinical research. Dr. Mauldin is scheduled to present preliminary outcomes data at the Veterinary Cancer Society’s annual conference in October, followed by peer-reviewed publication in 2020 and 2021.

 

In addition to dogs and cats, the 3,000 animals treated by PetCure include zoo animals and exotic pets such as a white tiger, a jaguar, a sea lion, a bearded dragon and a goat.

 

To view the PetCure offering click here: https://www.flashfunders.com/petcure

   

This press release is not a solicitation or offer to buy or sell securities. Investments may be speculative, illiquid and carry a risk of loss. Past performance is not indicative of future results. There is no guarantee that any specific outcome will be achieved.

About PetCure Oncology, LLC

Founded in 2014, PetCure Oncology’s mission is to provide pet families with support, knowledge and access to comprehensive and compassionate cancer care. PetCure Oncology has established a network of board-certified radiation oncologists and partnered with leading specialty animal hospitals across the country, providing a national network of comprehensive cancer centers with expertise in radiation oncology and stereotactic radiation (SRS/SRT), an advanced form of radiation therapy that may be effective in treating cancer. The first PetCure Oncology center opened in 2015 and the network aims to expand to seven centers in the fall of 2019 with additional sites under review. For more information, please visit www.petcureoncology.com

 

About Boustead Securities, LLC

Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com.

 

About Sutter Securities Group, Inc.

Headquartered in Irvine, California, Sutter Securities Group, Inc. (“SSG”), founded in 2013, through its affiliates, is an innovator and investment banking solutions provider. SSG owns and operates Sutter Securities Clearing, LLC, and Sutter Securities, Inc, FINRA member broker-dealers; Sutter Shareholder Services, LLC, a SEC-registered transfer agent; FlashFunders Funding Portal, LLC, a FINRA member funding portal; and Sutter Capital Management, Inc. SSG, through its affiliates, operates a U.S.-based online securities platform whose underlying technology and regulatory infrastructure are designed to enable issuers to engage in Regulation D, Regulation A (known as Reg A+), Regulation S, Regulation CF and fully registered S-1 and F-1 Initial Public Offerings in compliance with applicable federal, state and non-U.S. securities laws.   SSG is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. Additional information is available at www.flashfunders.com.

 

Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements provide our current expectations or forecasts of future events. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements in this announcement include, but are not limited to, statements regarding our disclosure concerning the Company’s operations, cash flows, financial position and dividend policy.

Share on Facebook
Share on Twitter
Please reload

Follow Us